There has recently been a setback at Biogen. At the beginning of the month, an FDA advisory committee was unimpressed by the drug candidate aducanumab in the fight against dementia. Morphosys is also working on a dementia drug. It is unclear whether these studies will be followed up after the Biogen setback.
For the analysts at FMR, this is of minor importance in terms of their model. The corresponding possibilities have not yet been taken into account. Therefore there is no need to make any changes to the estimates.
So the buy recommendation for the shares of Morphosys remains. The experts still see the price target at EUR 150.00.
For the current year the analysts at Morphosys expect earnings per share of EUR 0.51. In 2021 there should be a minus of 2.17 euros per paper, for 2022 the analysts are forecasting earnings per share of 1.58 euros.
The shares of Morphosys gain 1.3 percent in the afternoon to 90.16 euros. The share thus has strong upside potential.